Bayer sets up cell and gene platform to foster purchased biotech firms

Reuters

Published Dec 02, 2020 07:57

FRANKFURT (Reuters) - Bayer (DE:BAYGN) said it was setting up an organisation within its healthcare division to speed up and support cell and gene therapy development, following recent takeovers.

The new platform will provide services such as research, manufacturing, clinical development and project management to support the new business.